Regenerative Medicine Solutions

Yukio Fukushima Naokazu Kitamura Daisuke Iwayama, Ph.D. Kazuhito Matsuzaki Sena Yoshii Jun Taniguchi Toyoshige Kobayashi, Ph.D. Jun Otomo, Ph.D. OVERVIEW: There are growing expectations throughout the world for the practical commercialization of regenerative medicine, a new field of medical technology that can cure or restore function to diseased parts of the body by transplanting tissue or cells processed using advanced cell culture techniques that use cells as raw materials. Encouragement for commercialization is also anticipated in Japan where regulations on regenerative medicine came into force in November 2014. Hitachi already offers a wide range of in-house resources for cell production, including equipment and facilities, information systems, and services. In the future, in addition to the marketing of resources from within the group, Hitachi will also consider joint development with customers or collaborating with other companies if needed, aiming to adopt a “One Hitachi” approach to deploying a wide range of regenerative medicine solutions that can take on the challenges faced by customers. Hitachi also plans to play a part in the development of the regenerative medicine industry through extensive collaboration with industry organizations, companies, and other groups associated with the field.